The Pennsylvania Supreme Court has denied efforts by drugmaker Janssen Pharmaceuticals to overturn a $70 million verdict out of the Risperdal mass tort in Philadelphia. The decision paves the way for the trial court to reconsider whether the facts of the case merit a punitive damages trial.